Danny Vijey Jeyaraju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Danny Vijey Jeyaraju has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Aaron D. Schimmer
Princess Margaret Cancer Centre, University Health Network
9 shared publications Marcela Gronda
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9 shared publicationsRose Hurren
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9 shared publicationsXiaoming Wang
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
9 shared publications- Luca Pellegrini
Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Quebec, Canada
8 shared publications Mark D. Minden
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
8 shared publications
Latest Publications
- 1 June 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 26 (6) , 926-937.e10
Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal
- 1 June 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 26 (6) , 926-937.e10
Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal
- 1 June 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 24 (6) , 1007
The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids
- 1 June 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 24 (6) , 1007
The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids
- 1 April 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 24 (4) , 621-636.e16
The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids
- 1 April 2019
- Published by Elsevier in Cell Stem Cell
- Vol. 24 (4) , 621-636.e16
The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids
- Open Access
- 20 December 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (5) , 963-972
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia
Mitochondrial DNA encodes 13 proteins that comprise components of the respiratory chain that maintain oxidative phosphorylation. The replication of mitochondrial DNA is performed by the sole mitochondrial DNA polymerase γ. As acute myeloid leukemia cells and stem cells have an increased reliance on oxidative phosphorylation, we sought to evaluate polymerase γ inhibitors in acute myeloid leukemia. The thymidine dideoxynucleoside analogue, alovudine, is an inhibitor of polymerase γ. In acute myeloid leukemia cells, alovudine depleted mitochondrial DNA, reduced mitochondrial encoded proteins, decreased basal oxygen consumption, and decreased cell proliferation and viability. To evaluate the effects of polymerase γ inhibition with alovudine in vivo, mice were xenografted with OCI-AML2 cells and then treated with alovudine. Systemic administration of alovudine reduced leukemic growth without evidence of toxicity and decreased levels of mitochondrial DNA in the leukemic cells. We also showed that alovudine increased the monocytic differentiation of acute myeloid leukemia cells. Genetic knockdown and other chemical inhibitors of polymerase γ also promoted acute myeloid leukemia differentiation, but the effects on acute myeloid leukemia differentiation were independent of reductions in oxidative phosphorylation or respiratory chain proteins. Thus, we have identified a novel mechanism by which mitochondria regulate acute myeloid leukemia fate and differentiation independent of oxidative phosphorylation. Moreover, we highlight polymerase γ inhibitors, such as alovudine, as novel therapeutic agents for acute myeloid leukemia.
- 20 December 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (5) , 963-972
Open AccessThe thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia
Mitochondrial DNA encodes 13 proteins that comprise components of the respiratory chain that maintain oxidative phosphorylation. The replication of mitochondrial DNA is performed by the sole mitochondrial DNA polymerase γ. As acute myeloid leukemia cells and stem cells have an increased reliance on oxidative phosphorylation, we sought to evaluate polymerase γ inhibitors in acute myeloid leukemia. The thymidine dideoxynucleoside analogue, alovudine, is an inhibitor of polymerase γ. In acute myeloid leukemia cells, alovudine depleted mitochondrial DNA, reduced mitochondrial encoded proteins, decreased basal oxygen consumption, and decreased cell proliferation and viability. To evaluate the effects of polymerase γ inhibition with alovudine in vivo, mice were xenografted with OCI-AML2 cells and then treated with alovudine. Systemic administration of alovudine reduced leukemic growth without evidence of toxicity and decreased levels of mitochondrial DNA in the leukemic cells. We also showed that alovudine increased the monocytic differentiation of acute myeloid leukemia cells. Genetic knockdown and other chemical inhibitors of polymerase γ also promoted acute myeloid leukemia differentiation, but the effects on acute myeloid leukemia differentiation were independent of reductions in oxidative phosphorylation or respiratory chain proteins. Thus, we have identified a novel mechanism by which mitochondria regulate acute myeloid leukemia fate and differentiation independent of oxidative phosphorylation. Moreover, we highlight polymerase γ inhibitors, such as alovudine, as novel therapeutic agents for acute myeloid leukemia.
- 8 June 2018
- Published by Springer Nature in Leukemia
- Vol. 33 (1) , 37-51
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme in the ubiquitylation cascade in which proteins are tagged with ubiquitin moieties to regulate their degradation or function. Here, we evaluated TAK-243, a first-in-class UBA1 inhibitor, in preclinical models of AML. In AML cell lines and primary AML samples, TAK-243 induced cell death and inhibited clonogenic growth. In contrast, normal hematopoietic progenitor cells were more resistant. TAK-243 preferentially bound to UBA1 over the related E1 enzymes UBA2, UBA3, and UBA6 in intact AML cells. Inhibition of UBA1 with TAK-243 decreased levels of ubiquitylated proteins, increased markers of proteotoxic stress and DNA damage stress. In vivo, TAK-243 reduced leukemic burden and targeted leukemic stem cells without evidence of toxicity. Finally, we selected populations of AML cells resistant to TAK-243 and identified missense mutations in the adenylation domain of UBA1. Thus, our data demonstrate that TAK-243 targets AML cells and stem cells and support a clinical trial of TAK-243 in this patient population. Moreover, we provide insight into potential mechanisms of acquired resistance to UBA1 inhibitors.
- 8 June 2018
- Published by Springer Nature in Leukemia
- Vol. 33 (1) , 37-51
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme in the ubiquitylation cascade in which proteins are tagged with ubiquitin moieties to regulate their degradation or function. Here, we evaluated TAK-243, a first-in-class UBA1 inhibitor, in preclinical models of AML. In AML cell lines and primary AML samples, TAK-243 induced cell death and inhibited clonogenic growth. In contrast, normal hematopoietic progenitor cells were more resistant. TAK-243 preferentially bound to UBA1 over the related E1 enzymes UBA2, UBA3, and UBA6 in intact AML cells. Inhibition of UBA1 with TAK-243 decreased levels of ubiquitylated proteins, increased markers of proteotoxic stress and DNA damage stress. In vivo, TAK-243 reduced leukemic burden and targeted leukemic stem cells without evidence of toxicity. Finally, we selected populations of AML cells resistant to TAK-243 and identified missense mutations in the adenylation domain of UBA1. Thus, our data demonstrate that TAK-243 targets AML cells and stem cells and support a clinical trial of TAK-243 in this patient population. Moreover, we provide insight into potential mechanisms of acquired resistance to UBA1 inhibitors.
- Open Access
- 6 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (31) , 49777-49785
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
- 6 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (31) , 49777-49785
Open AccessA novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
- 1 June 2015
- Published by Elsevier in Cancer Cell
- Vol. 27 (6) , 864-876
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
- 1 June 2015
- Published by Elsevier in Cancer Cell
- Vol. 27 (6) , 864-876
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
- 29 March 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (6) , 811-820
Mitochondrial DNA damage by bleomycin induces AML cell death
Mitochondria contain multiple copies of their own 16.6 kb circular genome. To explore the impact of mitochondrial DNA (mtDNA) damage on mitochondrial (mt) function and viability of AML cells, we screened a panel of DNA damaging chemotherapeutic agents to identify drugs that could damage mtDNA. We identified bleomycin as an agent that damaged mtDNA in AML cells at concentrations that induced cell death. Bleomycin also induced mtDNA damage in primary AML samples. Consistent with the observed mtDNA damage, bleomycin reduced mt mass and basal oxygen consumption in AML cells. We also demonstrated that the observed mtDNA damage was functionally important for bleomycin-induced cell death. Finally, bleomycin delayed tumor growth in xenograft mouse models of AML and anti-leukemic concentrations of the drug induced mtDNA damage in AML cells preferentially over normal lung tissue. Taken together, mtDNA-targeted therapy may be an effective strategy to target AML cells and bleomycin could be useful in the treatment of this disease.
- 29 March 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (6) , 811-820
Mitochondrial DNA damage by bleomycin induces AML cell death
Mitochondria contain multiple copies of their own 16.6 kb circular genome. To explore the impact of mitochondrial DNA (mtDNA) damage on mitochondrial (mt) function and viability of AML cells, we screened a panel of DNA damaging chemotherapeutic agents to identify drugs that could damage mtDNA. We identified bleomycin as an agent that damaged mtDNA in AML cells at concentrations that induced cell death. Bleomycin also induced mtDNA damage in primary AML samples. Consistent with the observed mtDNA damage, bleomycin reduced mt mass and basal oxygen consumption in AML cells. We also demonstrated that the observed mtDNA damage was functionally important for bleomycin-induced cell death. Finally, bleomycin delayed tumor growth in xenograft mouse models of AML and anti-leukemic concentrations of the drug induced mtDNA damage in AML cells preferentially over normal lung tissue. Taken together, mtDNA-targeted therapy may be an effective strategy to target AML cells and bleomycin could be useful in the treatment of this disease.
- Open Access
- 26 March 2015
- Published by American Society of Hematology in Blood
- Vol. 125 (13) , 2120-2130
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress
Key Points: AML cells have increased mitochondrial mass, low respiratory chain complex activities, and low spare reserve capacity compared with normal cells. AML cells have heightened sensitivity to inhibitors of the respiratory chain complexes and oxidative stressors.
- 26 March 2015
- Published by American Society of Hematology in Blood
- Vol. 125 (13) , 2120-2130
Open AccessAML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress
Key Points: AML cells have increased mitochondrial mass, low respiratory chain complex activities, and low spare reserve capacity compared with normal cells. AML cells have heightened sensitivity to inhibitors of the respiratory chain complexes and oxidative stressors.
- 28 October 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (45) , 16017-16022
A Mitofusin-2–dependent inactivating cleavage of Opa1 links changes in mitochondria cristae and ER contacts in the postprandial liver
Significance: We provide, to our knowledge, the first in vivo quantitative description of the adaptive response of the mitochondrial reticulum to the metabolic transition occurring in the liver in the hours after feeding. When nutrients become limiting, mitochondria size, cristae density, and respiratory capacity drop, but mitochondria–ER contacts, which control calcium and lipids fluxes between these organelles, double. A proteolytic inactivation of Optic atrophy 1 (Opa1), a major regulator of fusion and cristae architecture, accompanies these changes and found to depend on Mitofusin-2, a key regulator of mitochondria–ER contact biogenesis. Thus, mitochondria adapt to nutrient depletion by coupling the molecular machineries that organize cristae architecture and mitochondria–ER contact assembly, which were previously thought to operate independently of each other.
- 28 October 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (45) , 16017-16022
A Mitofusin-2–dependent inactivating cleavage of Opa1 links changes in mitochondria cristae and ER contacts in the postprandial liver
Significance: We provide, to our knowledge, the first in vivo quantitative description of the adaptive response of the mitochondrial reticulum to the metabolic transition occurring in the liver in the hours after feeding. When nutrients become limiting, mitochondria size, cristae density, and respiratory capacity drop, but mitochondria–ER contacts, which control calcium and lipids fluxes between these organelles, double. A proteolytic inactivation of Optic atrophy 1 (Opa1), a major regulator of fusion and cristae architecture, accompanies these changes and found to depend on Mitofusin-2, a key regulator of mitochondria–ER contact biogenesis. Thus, mitochondria adapt to nutrient depletion by coupling the molecular machineries that organize cristae architecture and mitochondria–ER contact assembly, which were previously thought to operate independently of each other.